J&J suspends enrollment in clinical trial assessing Essa Pharma’s prostate cancer treatment

Shares of Essa Pharma Inc. fell 28.6% in premarket trading on Monday after the company said Johnson & Johnson suspended enrollment in a Phase 1 clinical trial for Essa’s experimental prostate cancer therapy, citing patient recruitment challenges. Essa had announced a clinical collaboration with J&J back in 2021. “We are in discussions with Janssen to supply abiraterone acetate and apalutamide for an ESSA-sponsored combination study and expect to provide more details in the coming months,” Essa CEO David Parkinson said in a news release. Essa’s stock is down 68.9% in 2022, while the S&P 500 has declined 18.5%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Previous post Pandora stock falls after fire at distribution center in Europe
Next post Verisk to sell Wood Mackenzie energy business for up to $3.3 billion in cash to Veritas Capital